1. Home
  2. BCS vs REGN Comparison

BCS vs REGN Comparison

Compare BCS & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCS
  • REGN
  • Stock Information
  • Founded
  • BCS 1690
  • REGN 1988
  • Country
  • BCS United Kingdom
  • REGN United States
  • Employees
  • BCS N/A
  • REGN N/A
  • Industry
  • BCS Commercial Banks
  • REGN Biotechnology: Pharmaceutical Preparations
  • Sector
  • BCS Finance
  • REGN Health Care
  • Exchange
  • BCS Nasdaq
  • REGN Nasdaq
  • Market Cap
  • BCS 64.3B
  • REGN 59.5B
  • IPO Year
  • BCS N/A
  • REGN 1991
  • Fundamental
  • Price
  • BCS $20.28
  • REGN $580.41
  • Analyst Decision
  • BCS Hold
  • REGN Buy
  • Analyst Count
  • BCS 1
  • REGN 21
  • Target Price
  • BCS N/A
  • REGN $808.43
  • AVG Volume (30 Days)
  • BCS 16.0M
  • REGN 976.4K
  • Earning Date
  • BCS 07-29-2025
  • REGN 08-01-2025
  • Dividend Yield
  • BCS 2.14%
  • REGN 0.61%
  • EPS Growth
  • BCS 58.77
  • REGN 5.03
  • EPS
  • BCS 0.55
  • REGN 39.67
  • Revenue
  • BCS $35,147,280,453.00
  • REGN $14,214,200,000.00
  • Revenue This Year
  • BCS $18.26
  • REGN N/A
  • Revenue Next Year
  • BCS $4.71
  • REGN $6.65
  • P/E Ratio
  • BCS $8.52
  • REGN $14.63
  • Revenue Growth
  • BCS 10.34
  • REGN 5.38
  • 52 Week Low
  • BCS $11.22
  • REGN $476.49
  • 52 Week High
  • BCS $20.56
  • REGN $1,211.20
  • Technical
  • Relative Strength Index (RSI)
  • BCS 63.64
  • REGN 60.80
  • Support Level
  • BCS $19.15
  • REGN $544.16
  • Resistance Level
  • BCS $20.56
  • REGN $572.58
  • Average True Range (ATR)
  • BCS 0.29
  • REGN 16.66
  • MACD
  • BCS 0.04
  • REGN 0.75
  • Stochastic Oscillator
  • BCS 83.90
  • REGN 93.11

About BCS Barclays PLC

Barclays is a universal bank headquartered in the United Kingdom. It operates via five principal segments; UK (retail), UK corporate bank, private bank and wealth management, investment bank, and US consumer bank. In its UK segment, the bank provides current accounts, mortgages, savings and investment management services, credit cards, and business banking services to retail clients and small and medium-size enterprises. The international segment includes a corporate bank offering banking solutions to large corporates, a bulge-bracket global investment bank, and a credit card and payments business.

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Share on Social Networks: